Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

被引：0
|
作者：
Yarlas, Aaron [1 ]
Merlini, Giampaolo [2 ,3 ]
White, Michelle K. [1 ]
Kessler, Asia Sikora [1 ]
Lovley, Andrew [1 ]
Guthrie, Spencer D. [4 ]
Pollock, Michael [4 ]
Gertz, Morie A. [5 ]
机构：
[1] Optum, Johnston, RI USA
[2] Fdn IRCCS Policlin San Matteo, Amyloidosis Res & Treatment Ctr, Dept Mol Med, Pavia, Italy
[3] Univ Pavia, Pavia, Italy
[4] Akcea Therapeut, Cambridge, MA USA
[5] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-119216
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4803
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial
    Yarlas, Aaron
    Merlini, Giampaolo
    White, Michelle K.
    Kessler, Asia Sikora
    Lovley, Andrew
    Guthrie, Spencer D.
    Pollock, Michael
    Gertz, Morie A.
    BLOOD, 2018, 132
  • [2] IMPACT OF INOTERSEN ON GENERIC HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS WITH HATTR AMYLOIDOSIS: RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    Yarlas, A.
    Kessler, Sikora A.
    Lovley, A.
    Guthrie, S.
    Pollock, M.
    White, M. K.
    VALUE IN HEALTH, 2018, 21 : S354 - S354
  • [3] IMPACT OF INOTERSEN ON CONDITION-SPECIFIC QUALITY OF LIFE (QOL) FOR PATIENTS WITH HATTR AMYLOIDOSIS: RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    Kessler, Sikora A.
    Yarlas, A.
    Lovley, A.
    Guthrie, S.
    Pollock, M.
    White, M. K.
    VALUE IN HEALTH, 2018, 21 : S354 - S354
  • [4] Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial
    Romano, Silvia
    Coarelli, Giulia
    Marcotulli, Christian
    Leonardi, Luca
    Piccolo, Francesca
    Spadaro, Maria
    Frontali, Marina
    Ferraldeschi, Michela
    Vulpiani, Maria Chiara
    Ponzelli, Federica
    Salvetti, Marco
    Orzi, Francesco
    Petrucci, Antonio
    Vanacore, Nicola
    Casali, Carlo
    Ristori, Giovanni
    LANCET NEUROLOGY, 2015, 14 (10): : 985 - 991
  • [5] A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MAXEPA IN STROKE PATIENTS
    GREEN, D
    BARRERAS, LR
    BORENSZTAJN, J
    REDDY, N
    ROVNER, R
    SIMON, H
    CLINICAL RESEARCH, 1984, 32 (02): : A309 - A309
  • [6] The cult of the double-blind placebo-controlled trial
    Ellis, SJ
    Adams, RF
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1997, 51 (01): : 36 - 39
  • [7] A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF FLUOXETINE IN PATIENTS WITH FIBROMYALGIA
    WOLFE, F
    CATHEY, MA
    HAWLEY, DJ
    ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : S220 - S220
  • [8] Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients
    Higuchi, Teruhiko
    Ishigooka, Jun
    Iyo, Masaomi
    Yeh, Chin-Bin
    Ebenezer, Esther Gunaseli
    Liang, Kuei Yu
    Lee, Jung Sik
    Lee, Sang Yeol
    Lin, Shih Ku
    Yoon, Bo-Hyun
    Nakamura, Masatoshi
    Hagi, Katsuhiko
    Sato, Takayuki
    ASIA-PACIFIC PSYCHIATRY, 2019, 11 (02)
  • [9] CISAPRIDE IN CHRONIC DYSPEPSIA - RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    CHUNG, JM
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 : 11 - 14
  • [10] ALBENDAZOLE IN HUMAN LOIASIS - RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    KLION, AD
    MASSOUGBODJI, A
    HORTON, J
    EKOUE, S
    LANMASSO, T
    AHOUISSOU, NL
    NUTMAN, TB
    JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (01): : 202 - 206
12345